CBD Market

UK Advertising Standards Agency upholds CBD advert complaint

The ASA has ruled that the advert breached the UK Code of Broadcast Advertising rules 13.6 and 13.6.2.

UK Advertising Standards Agency upholds CBD advert complaint

The Advertising Standards Authority (ASA) has upheld two complaints against a CBD advert that appeared on the Gemporia television channel on 22 May 2021.

The UK’s advertising regulator, the ASA, has conducted an investigation into a teleshopping presentation for ProLife CBD Oils, which featured on Gemporia, and made numerous claims about the health benefits of the CBD products.

Featuring a presenter from Gemporia and one of the co-founders from ProLife CBD, the advert made reference that the products were registered with the Food Standards Agency (FSA), and claimed the products could help with conditions such as schizophrenia, mad cow disease, sickle cell anaemia, addiction, and antibiotic resistance, amongst other health conditions.

The claims were challenged on whether the advert was misleading, whether the oils are effective for treating the claimed conditions, and whether the health claims complied with the UK Code of Broadcast Advertising (BCAP). 

The ASA ruled that the presentation breached the BCAP Code rules 13.6 and 13.6.2, related to food, food supplements and associated health or nutrition claims.

In response to the complaints, the ASA noted that “Gemporia said they were not able to substantiate the claims or demonstrate that they were authorised claims in the Great Britain nutrition and health claims (NHC) Register (the NHC Register)”, and that “they had understood that because a Novel Foods application had been submitted to the FSA, the products were allowed to be marketed and any references made in relation to this were based on that assumption, but that they had misunderstood the context.”

The ASA said: “The ASA considered that consumers would understand from the presentation that ProLife CBD oils could treat or help with all the conditions that were mentioned, including those that appeared on the two presentation slides, in the testimonials and those mentioned by the presenters. 

“We concluded the claims implied the product, a food, prevented, treated or cured human disease, which was prohibited under the Code.”

[activecampaign form=31]

Topicscannabis industrycbdCBD productsregulation

Stephanie Price

Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine 'Game Theory' focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on "Medical Cannabis Explained".

More from Stephanie

Spotted an error, or have a tip? Contact the newsroom.

Up next · CBD Market

California’s Beard Bros Enters UK and European CBD Markets Through BRITISH CANNABIS Partnership

BusinessOfCannabis · 12 October 2026

More